Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Papillary fibroelastoma

Papillary fibroelastoma is a benign endocardial lesion composed of branching connective-tissue fronds covered by endothelium and often joined to a small stalk. It develops mainly on cardiac valves, particularly the aortic and mitral valves, but may also arise from other endocardial surfaces. Its clinical importance derives primarily from the risk of embolism: a lesion measuring only a few millimeters may be associated with cerebral, retinal or coronary ischemia without significantly impairing valve function. Small size and lack of invasion therefore do not imply absence of danger.
The term fibroelastoma refers to the fibrous and elastic components of the fronds, while papillary describes their arrangement. Classification among benign cardiac tumors is well established, although the biological nature and mechanisms of formation remain incompletely understood. In clinical practice, a lesion suspected on echocardiography must be distinguished from a histologically confirmed diagnosis because small vegetations, valvular excrescences and thrombi may produce similar images.

Prevalence in the general population has not been precisely defined. Detection has increased with wider use of transesophageal echocardiography and greater attention to cardiac embolic sources. Pathological and surgical series place fibroelastoma among the primary cardiac tumors most frequently identified in adults, but proportions depend strongly on patient selection. In the series by Sun and colleagues, involving 162 patients with pathological confirmation, lesions were usually solitary and valvular, with mean dimensions below one centimeter.
Diagnosis is more common in adulthood, often at advanced ages, and may be entirely incidental. No clinical risk profile has been identified that reliably predicts who will develop the lesion. Moreover, patients with incidental findings and those evaluated after a stroke represent different populations, from which interchangeable estimates of future risk cannot be derived.

Etiology, pathogenic hypotheses and lesion structure

The origin of fibroelastoma remains uncertain. Proposed mechanisms include a hamartomatous process, a response to endocardial injury and progressive organization of small thrombotic deposits. The relationship among mechanical stress, endothelial lining and fibrin deposition provides a plausible model for some valvular locations, but it is not an experimentally demonstrated explanation for all cases. Occasional occurrence after cardiac surgery or treatments that may damage the endocardium supports a possible role for acquired factors without establishing a necessary causal relationship.

Fibroelastoma must not be interpreted as an inevitable consequence of atherosclerosis, aging or infection. These conditions may coexist and affect patient assessment but do not define the lesion's etiology. No common specific inherited syndrome is recognized that would justify genetic testing or echocardiographic screening of relatives in every sporadic case. Even the discovery of multiple lesions first requires anatomical confirmation and a careful differential diagnosis, without automatically attributing them to a Mendelian predisposition.

Grossly, the fronds may spread out when the specimen is immersed in fluid, producing the characteristic sea-anemone appearance. This description refers to the anatomical specimen and is not an obligatory echocardiographic criterion. Each frond contains a relatively paucicellular core of collagen and elastic fibers, with extracellular matrix components, covered by a single endothelial layer. The absence of a true vascular network within the fronds helps distinguish the lesion from vascular tumors and partly explains its behavior in contrast studies.
The papillary structure is delicate and offers a large surface in contact with blood. Platelet and fibrin deposits may adhere to the fronds, adding a thrombotic component to the lesion's tissue. Embolized material may therefore have a composition different from the fibroelastic core alone.

The attachment site is often small, with a mobile mass connected to the endocardium by a stalk. Valvular lesions may arise from different leaflet surfaces and should not be excluded simply because they do not occupy a supposedly classic site. Nonvalvular locations include the ventricular endocardium, subvalvular apparatus and atrial surfaces, among others. Recognition of these variants avoids limiting the search to aortic and mitral leaflets alone when clinical suspicion remains high.

Pathophysiology of embolic risk and cardiac manifestations

The principal mechanism of injury is detachment of embolic material from the fronds or from surface thrombi. Repeated oscillations of the mass during the cardiac cycle may favor mechanical stress and release of material. In left-sided lesions, blood carries it into the systemic circulation, potentially causing cerebral, retinal, coronary or peripheral events. A right-sided fibroelastoma primarily threatens the pulmonary circulation; systemic embolization from a right-sided source requires a suitable right-to-left passage, such as an intracardiac communication under the appropriate conditions.

Mobility has important clinical significance. In the analysis of 725 published cases by Gowda and colleagues, it was associated with fibroelastoma-related events. This finding supports attention to independent movement of the mass but comes from heterogeneous literature subject to case selection. It does not allow an exact individual risk to be assigned from a single parameter. Location, embolic history, diagnostic reliability and patient characteristics must be considered together.

The relationship between size and risk is not linear. A small lesion may be highly mobile and carry thrombotic material; a larger one may remain stable. The one-centimeter threshold often used in management proposals for asymptomatic lesions is a practical reference, not a biological cutoff that separates harmless from dangerous masses. Even measurements need cautious interpretation because visualization of the fronds, the echocardiographic plane and the phase of the cardiac cycle may alter them.
Growth rate is poorly defined and variable. Lack of enlargement over several assessments does not establish zero embolic risk, because the mechanism may depend on surface and movement more than on volume expansion.

Valve function is often preserved. The stalk may occupy a limited area without destroying the leaflet or preventing coaptation; consequently, a patient may have a hemodynamically normal valve and a significant embolic source. Regurgitation or obstruction directly attributable to the mass is less common and depends on location and anatomical relationships. For an aortic lesion, proximity to the coronary ostia may add mechanical interference to the risk of coronary embolism, a rare but potentially serious event.

Clinical presentation, history and physical examination

Fibroelastoma is frequently identified during an examination requested for another reason. In this setting, the history should nevertheless look for episodes compatible with previously unrecognized embolism: transient focal deficits, sudden visual disturbances or peripheral ischemia. Nonspecific symptoms alone, such as dizziness or fatigue, do not establish causation by the mass. The task is to determine whether a plausibly related, documentable manifestation exists, without classifying every lesion discovered in a patient with nonspecific complaints as symptomatic.

When presentation is a stroke or transient ischemic attack, assessment reconstructs the vascular territory, the appearance of cerebral lesions, possible recurrences and the timing of the cardiac finding. Events in different territories may make a central embolic source more plausible, but atrial fibrillation, carotid disease, aortic atheroma and other causes must also be examined. Temporal association with fibroelastoma is not automatic proof, especially in an older patient with multiple risk factors. Joint neurological and cardiological evaluation allows more robust attribution.

Acute chest pain, syncope, dyspnea or palpitations require distinguishing coronary or hemodynamic involvement from common coexisting heart disease. Right-sided lesions may be associated with pulmonary embolism, but venous thromboembolism is a much more common diagnosis and should be investigated when appropriate. Fever, chills, recent procedures, infections and device use instead suggest a possible infectious process that could mimic the lesion. A history of cancer, autoimmune disease or recurrent thrombosis heightens concern for sterile vegetations.

Reviewing previous studies may clarify whether the mass was already visible, whether it was described as a valvular excrescence and whether measurements are truly comparable. Antithrombotic therapy taken before an event must be documented precisely: ischemia despite anticoagulation does not itself prove tumor embolism, but underscores that protection from thrombotic material and protection from detachment of tissue are not equivalent. Previous cardiac surgery or chest radiotherapy belong in the clinical history but are not sufficient to establish the cause of the fibroelastoma.

The physical examination is often normal from a cardiac standpoint. Auscultation may reveal no murmurs because leaflet coaptation remains intact; absence of a significant valve finding therefore does not exclude an emboligenic lesion. Hemodynamic stability, rhythm, pulses and signs of peripheral ischemia are assessed along with a neurological examination appropriate to the presentation. Fever, peripheral signs of endocarditis or new destructive murmurs change the differential diagnosis. No pathognomonic clinical finding can identify fibroelastoma without imaging.

Echocardiographic investigations and differential diagnosis

Transthoracic echocardiography is often the first test. The typical finding is a small, mobile, rounded or lobulated mass, sometimes pedunculated, with a discernible central component and a finely irregular surface. The edge may appear shimmering because of frond movement, but this depends on resolution and is not invariably present. The valve or surface of origin, leaflet side, dimensions, attachment base, independent mobility and effects on flow should be documented.
Reproducibility in multiple planes is essential: an artifact, calcification or segment of a chord may mimic a lesion in a single view. The report should describe what is actually visible, distinguishing suspected fibroelastoma from tissue confirmation.

Transesophageal echocardiography plays a central role when the mass is small, the transthoracic window is inadequate or the search for an embolic source remains incomplete. It often provides better visualization of the stalk and fronds and may detect additional lesions. Three-dimensional acquisitions help locate the attachment relative to valvular segments, while two-dimensional imaging remains important for fine detail and motion. A lesion not seen on a technically limited transthoracic examination cannot be considered excluded.

Doppler evaluates regurgitation and stenosis and documents the function of a valve that may undergo valve-sparing surgery. Exploration should not stop at the first finding: the left atrial appendage, the accessible aorta and other valvular surfaces may contain competing embolic sources. A right-sided mass in a patient with systemic embolism also requires checking whether the proposed mechanism is anatomically possible. A search for shunts is guided by the overall picture, without assuming that every small patent foramen ovale necessarily caused the event.

Magnetic resonance imaging is not mandatory for every suspected fibroelastoma. Small size and rapid movement may limit detection and characterization; failure to visualize a clear mass on MRI does not negate a convincing echocardiographic finding. The method may be useful for larger or nonvalvular lesions, particularly when composition or a different origin is in question. Cardiac CT can clarify anatomical relationships and, in selected patients, the coronary arteries, but has limitations for very thin, mobile fronds.
PET is not a routine test to confirm fibroelastoma. Additional techniques should address a specific question, avoiding an automatic series of tests that does not improve the decision beyond good transesophageal echocardiography.

Distinguishing it from Lambl's excrescences is a frequent challenge. The latter are generally thin, filiform structures along valve closure lines; fibroelastoma tends to have a bulkier, organized and sometimes pedunculated component. Overlap nevertheless occurs, especially in small lesions, and echocardiography cannot always make a definitive distinction. Terminology must reflect uncertainty when present. Labeling every strand as fibroelastoma can overestimate risk and lead to unjustified interventions.

Infective vegetations are assessed by integrating blood cultures, clinical context and evidence of valvular or perivalvular damage. Fever, bacteremia, new destructive regurgitation or abscess favor endocarditis; their absence lowers certain probabilities without excluding all infectious forms. Empirical antibiotic treatment is not a diagnostic test for fibroelastoma. When endocarditis is genuinely suspected, the evaluation follows specific recommendations and includes appropriate microbiological sampling before therapy whenever the patient's condition allows it.

Nonbacterial thrombotic vegetations may accompany malignancy or autoimmune disease and present with systemic embolism. Their identification fundamentally changes treatment because the mass reflects a systemic disease. Valvular thrombi, prosthetic material, sutures, degenerative nodules and calcifications also enter the differential according to location. A cardiac myxoma more often arises from the atrial septum and has a different structure, but unusual sites require anatomical reasoning rather than classification by frequency alone.

No blood biomarker of fibroelastoma or set of official diagnostic criteria makes echocardiographic recognition infallible. Laboratory tests focus on alternatives, especially infection, thrombosis and systemic disease. Confirmation is histopathological, usually after resection, based on the endothelial-lined fibroelastic fronds. Preliminary biopsy of a small mobile valvular mass is not normally indicated: it can injure the valve or cause embolization without an advantage over planned excision.

Risk assessment and investigations after detection

Once the lesion is identified, decision-making must distinguish three questions: how reliable the diagnosis is, whether an event can be attributed to the lesion, and what the treatment risk is. A highly mobile left-sided mass in a patient with plausibly related embolism differs from a questionable strand found incidentally. Biological age, frailty, comorbidities, previous operations and the possibility of preserving the valve change the expected benefit of surgery. Size alone cannot summarize this balance.

After a neurological event, ischemia or hemorrhage must be characterized and the search for competing causes completed. Any rhythm monitoring addresses suspected atrial fibrillation and should not be omitted merely because a mass has been found. In peripheral or coronary embolism, investigations are tailored to the affected territory and urgency. Renal function, hematological status and ongoing therapies help prepare for intervention and estimate bleeding risk.

Preoperative imaging establishes the attachment, number of lesions and their relationships with the valve. The possibility of valve-sparing excision also depends on pre-existing valvular degeneration, which must be distinguished from effects of the mass. Coronary investigation follows individual clinical and surgical indications; catheterization is not automatically required for every patient with fibroelastoma. For an aortic lesion near the ostia, planning places particular emphasis on anatomy and procedural safety.
A typical fibroelastoma does not require systemic oncological staging or routine family screening. If the finding is uncertain and immediate risk is low, scheduled follow-up echocardiography can help clarify it, provided the method, interval and indications for earlier reassessment have been defined.

Surgical treatment, observation and antithrombotic therapy

Surgical resection is generally favored in patients with embolism or other manifestations plausibly attributable to fibroelastoma when operative risk is acceptable. The goal is to eliminate the source and obtain tissue diagnosis, ideally preserving the valve. Following a stroke, timing is agreed upon in conjunction with neurological assessment: infarct extent, hemorrhagic component and need for anticoagulation during cardiopulmonary bypass must be weighed against the risk of another event. No single mandatory interval applies to every presentation.

For asymptomatic lesions, the choice is less well defined. Left-sided location, high mobility, a clearly identifiable mass, larger size or the need for another cardiac operation may favor removal. Frailty, important comorbidities, uncertain diagnosis and high operative risk may favor observation. Using a diameter above one centimeter as a decision factor must not become an exclusive rule: smaller lesions may embolize, and a larger size does not remove the need to consider procedural risk.

Evidence supporting surgery mainly comes from observational studies. Tamin and colleagues analyzed 511 patients, distinguishing 185 resected, histologically confirmed lesions from 326 echocardiographically suspected lesions that were not removed. In the latter group, the reported cumulative stroke risk was 6% at one year and 13% at five years. These values underline the clinical relevance of the problem but do not represent the risk of every small incidental fibroelastoma: groups differed in selection, clinical conditions and diagnostic certainty, and the comparison was not randomized. The data therefore do not allow a precise causal reduction in risk to be attributed solely to surgery.

During surgery, the mass is removed while taking care to avoid fragmentation. On structurally preserved valves, valve-sparing resection confined to the mass and its attachment is often possible. Valve repair or replacement is reserved for cases in which the base, leaflet damage or associated valvular disease requires it. In Tamin's series, the native valve was preserved in nearly all patients operated on primarily for valvular fibroelastoma; this describes a real possibility, not a guarantee for every anatomy.
Intraoperative echocardiography assesses the result, valve competence and any further lesions. The specimen is submitted for histology because pathological findings can revise the preoperative diagnosis.

The choice between a conventional approach and a minimally invasive one depends on location, associated procedures and center experience. The essential principle is safe removal with preservation of function rather than a particular incision. For nonvalvular tumors, the strategy is adapted to the attachment. For right-sided lesions, less represented in case series, indications take account of pulmonary embolism, obstruction, mobility, any shunt and surgical risk without automatically transferring all proposals developed for left-sided lesions.

When surgery is deferred or ruled out, antiplatelet or anticoagulant treatment may be considered individually, especially after embolic events or with concomitant indications. No randomized trials demonstrate which strategy effectively prevents events attributable to fibroelastoma. Anticoagulation may act on surface thrombus but does not dissolve the fibroelastic core and does not necessarily prevent detachment of the fronds. Bleeding risk must therefore be balanced against a specific, unquantified benefit, without presenting medication as a proven equivalent to resection.

Long-term antithrombotic therapy after removal is not mandatory solely because the patient had fibroelastoma. It may be needed for atrial fibrillation, prostheses, vascular disease or other conditions under their respective indications. Likewise, chemotherapy, radiotherapy and antibiotics have no routine role for a confirmed noninfectious lesion. Medical management must separate the tumor problem from other reasons for taking cardiovascular medications.

Percutaneous removal techniques have been described in selected patients with high or prohibitive surgical risk. The series by Seby and colleagues documents transcatheter approaches using cerebral embolic protection. Experience remains limited, with embolization, valve injury and incomplete removal as central risks. These procedures are not an equivalent standard to surgery for all patients and require multidisciplinary selection and specific expertise.

Prognosis, recurrence and echocardiographic surveillance

After effective resection, prognosis is generally favorable and the identified anatomical source is removed. Overall outcome nevertheless depends on injury already sustained, associated heart disease and other cerebrovascular risk factors. A patient operated on after a stroke may retain neurological disability, while subsequent ischemia may be caused by atrial fibrillation or atherosclerosis without indicating recurrence. Clinical follow-up must therefore assess the whole patient, not only the site from which the mass was removed.

The possibility of recurrence deserves attention. Early series reported very low frequencies, whereas studies with longer surveillance have identified new findings compatible with fibroelastoma. Among 98 patients with at least one year of echocardiographic follow-up after histologically confirmed removal, Sorour and colleagues identified 12 suspected recurrences. Three were resected again: two proved to be fibroelastomas and one a Lambl's excrescence. These figures distinguish echocardiographic reappearance from pathological confirmation and show why every new image cannot automatically be equated with the same neoplasm.

In the surgical series by Mazur and colleagues, involving 294 patients, the estimated recurrence rate at ten years was 15.8%. Percentages across series are not directly comparable because follow-up duration, examination methods, selection and event definitions differ. Possible explanations include initially missed lesions, new lesions at other sites and local residual disease; detection years later does not identify the mechanism by itself. These observations support surveillance after resection and correct the notion that recurrence is impossible.

A postoperative echocardiogram documents valve function and establishes a reference. Subsequent examinations are tailored to the number and location of lesions, image quality, any concern about residual tissue and embolic history. A transesophageal examination may be required if transthoracic imaging is unreliable or a new suspicion arises. No universally validated schedule of frequency and duration exists for every patient.
In nonoperated individuals, surveillance must assess mobility, size, valve function and any symptoms. Stability of one parameter does not settle the problem; a new embolic event or morphological change requires revisiting the indication. The plan should also specify how to manage sudden symptoms, because waiting until the scheduled examination is inappropriate in the presence of a possible acute neurological or vascular event.

Complications of the lesion and its treatments

The dominant complication is embolism, which may cause stroke, visual loss, peripheral ischemia or myocardial infarction. Severity depends on the territory and extent of occlusion, not necessarily on the size of the original lesion. Coronary involvement may result from embolization or, with particular anatomical relationships, interference with an ostium. Cardiac arrest and sudden death have been described, but their rarity and reporting selection preclude translating these observations into a quantitative prediction for every incidental finding.

Intracardiac obstruction and valvular dysfunction are less frequent but possible when location, mobility and volume interfere with flow or coaptation. Right-sided forms may cause pulmonary embolization. After a neurological event, persistence of the mass creates a risk of recurrent ischemia, while antithrombotic therapy may add bleeding risk without eliminating the embolic risk. This balance must be updated over time rather than fixed once and for all at discovery.

Procedural complications include embolization during manipulation, bleeding, valve damage or regurgitation, arrhythmias and neurological events. Their likelihood depends on patient, anatomy, access and concomitant procedures. A new mass after surgery requires distinguishing recurrence from thrombus, excrescence and surgical material. Diagnostic error can also have consequences: calling an infective vegetation a fibroelastoma delays needed treatment, while labeling a simple degenerative strand with that name may lead to avoidable surgery. Diagnostic accuracy, treatment selection and long-term follow-up are therefore inseparable parts of management.

References
  1. Gowda RM et al. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. American Heart Journal. 2003;146(3):404-410.
  2. Sun JP et al. Clinical and echocardiographic characteristics of papillary fibroelastomas: a retrospective and prospective study in 162 patients. Circulation. 2001;103(22):2687-2693.
  3. Klarich KW et al. Papillary fibroelastoma: echocardiographic characteristics for diagnosis and pathologic correlation. Journal of the American College of Cardiology. 1997;30(3):784-790.
  4. Tamin SS et al. Prognostic and Bioepidemiologic Implications of Papillary Fibroelastomas. Journal of the American College of Cardiology. 2015;65(22):2420-2429.
  5. Mazur P et al. Operative management of cardiac papillary fibroelastomas. The Journal of Thoracic and Cardiovascular Surgery. 2024;167(3):1088-1097.e2.
  6. Sorour AA et al. Recurrence of Pathologically Proven Papillary Fibroelastoma. The Annals of Thoracic Surgery. 2022;113(4):1208-1214.
  7. Kurmann R et al. Cardiac Masses Discovered by Echocardiogram; What to Do Next? Structural Heart. 2023;7(4):100154.
  8. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  9. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  10. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  11. Cohen A et al. EACVI recommendations on cardiovascular imaging for the detection of embolic sources: endorsed by the Canadian Society of Echocardiography. European Heart Journal - Cardiovascular Imaging. 2021;22(6):e24-e57.
  12. Delgado V et al. 2023 ESC Guidelines for the management of endocarditis. European Heart Journal. 2023;44(39):3948-4042.
  13. Seby R et al. Percutaneous Removal of Cardiac Papillary Fibroelastomas. JACC: Case Reports. 2024;29(24):102843.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.